drugset / Trial / NCT02074358

A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects

NCT02074358

Phase 1 Completed 43 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to assess the effect of two 4-Factor PCC formulations on Apixaban pharmacodynamics in healthy adult subjects.

Timeline

Start
2014-02
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 10 mg Oral
Subject Beriplex P/N Protein / enzyme biologic 50 iu/kg Intravenous
Subject Cofact Protein / enzyme biologic 50 iu/kg Intravenous

Indications

No indication recorded.